Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, Dardaei L, Prutisto-Chang K, Dagogo-Jack I, Timofeevski S, Hubbeling H, Gainor JF, Ferris LA, Riley AK, Kattermann KE, Timonina D, Heist RS, Iafrate AJ, Benes CH, Lennerz JK, Mino-Kenudson M, Engelman JA, Johnson TW, Hata AN, Shaw AT.

Cancer Discov. 2018 Apr 12. pii: CD-17-1256. doi: 10.1158/2159-8290.CD-17-1256. [Epub ahead of print]

PMID:
29650534
2.

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.

Dardaei L, Wang HQ, Singh M, Fordjour P, Shaw KX, Yoda S, Kerr G, Yu K, Liang J, Cao Y, Chen Y, Lawrence MS, Langenbucher A, Gainor JF, Friboulet L, Dagogo-Jack I, Myers DT, Labrot E, Ruddy D, Parks M, Lee D, DiCecca RH, Moody S, Hao H, Mohseni M, LaMarche M, Williams J, Hoffmaster K, Caponigro G, Shaw AT, Hata AN, Benes CH, Li F, Engelman JA.

Nat Med. 2018 May;24(4):512-517. doi: 10.1038/nm.4497. Epub 2018 Mar 5.

PMID:
29505033
3.

A novel antibody-based approach to detect the functional ERCC1-202 isoform.

Kuo MS, Adam J, Dorvault N, Robin A, Friboulet L, Soria JC, Olaussen KA.

DNA Repair (Amst). 2018 Apr;64:34-44. doi: 10.1016/j.dnarep.2018.02.002. Epub 2018 Feb 11.

PMID:
29482102
4.

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.

Ricordel C, Friboulet L, Facchinetti F, Soria JC.

Ann Oncol. 2018 Jan 1;29(suppl_1):i28-i37. doi: 10.1093/annonc/mdx705.

PMID:
29462256
5.

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade.

Touat M, Sourisseau T, Dorvault N, Chabanon RM, Garrido M, Morel D, Krastev DB, Bigot L, Adam J, Frankum JR, Durand S, Pontoizeau C, Souquère S, Kuo MS, Sauvaigo S, Mardakheh F, Sarasin A, Olaussen KA, Friboulet L, Bouillaud F, Pierron G, Ashworth A, Lombès A, Lord CJ, Soria JC, Postel-Vinay S.

J Clin Invest. 2018 Apr 2;128(4):1671-1687. doi: 10.1172/JCI90277. Epub 2018 Mar 19.

6.

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, Hubbeling HG, Dardaei L, Farago AF, Schultz KR, Ferris LA, Piotrowska Z, Hardwick J, Huang D, Mino-Kenudson M, Iafrate AJ, Hata AN, Yeap BY, Shaw AT.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00063. Epub 2017 Aug 16.

7.

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.

Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, Dicecca R, Greenberg M, Kattermann KE, Riley AK, Fintelmann FJ, Rizzo C, Piotrowska Z, Shaw AT, Gainor JF, Sequist LV, Niederst MJ, Engelman JA, Benes CH.

Cell Rep. 2017 Dec 12;21(11):3298-3309. doi: 10.1016/j.celrep.2017.11.051.

8.

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.

Facchinetti F, Rossi G, Bria E, Soria JC, Besse B, Minari R, Friboulet L, Tiseo M.

Cancer Treat Rev. 2017 Apr;55:83-95. doi: 10.1016/j.ctrv.2017.02.010. Epub 2017 Mar 12. Review.

PMID:
28342334
9.

Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.

Facchinetti F, Caramella C, Auger N, Planchard D, Adam J, Lacroix L, Remon J, Massard C, Soria JC, Friboulet L, Besse B.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000520.

PMID:
27197808
10.

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT.

Cancer Discov. 2016 Oct;6(10):1118-1133. Epub 2016 Jul 18.

11.

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.

Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L.

Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. Epub 2016 Jul 11.

12.

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.

Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N.

EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.

13.

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, Katayama R, Iafrate AJ, Le L, McTigue M, Getz G, Johnson TW, Engelman JA.

N Engl J Med. 2016 Jan 7;374(1):54-61. doi: 10.1056/NEJMoa1508887. Epub 2015 Dec 23.

14.

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, Timofeevski S, Katayama R, Dinh DM, Lam H, Lam JL, Yamazaki S, Hu W, Patel B, Bezwada D, Frias RL, Lifshits E, Mahmood S, Gainor JF, Affolter T, Lappin PB, Gukasyan H, Lee N, Deng S, Jain RK, Johnson TW, Shaw AT, Fantin VR, Smeal T.

Cancer Cell. 2015 Jul 13;28(1):70-81. doi: 10.1016/j.ccell.2015.05.010. Epub 2015 Jul 2.

15.

Therapeutic management of ALK+ nonsmall cell lung cancer patients.

Duchemann B, Friboulet L, Besse B.

Eur Respir J. 2015 Jul;46(1):230-42. doi: 10.1183/09031936.00236414. Epub 2015 Apr 30. Review.

16.

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.

Gainor JF, Tan DS, De Pas T, Solomon BJ, Ahmad A, Lazzari C, de Marinis F, Spitaleri G, Schultz K, Friboulet L, Yeap BY, Engelman JA, Shaw AT.

Clin Cancer Res. 2015 Jun 15;21(12):2745-52. doi: 10.1158/1078-0432.CCR-14-3009. Epub 2015 Feb 27.

17.

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, Lee D, Kalsy A, Gomez-Caraballo M, Elamine L, Howe E, Hur W, Lifshits E, Robinson HE, Katayama R, Faber AC, Awad MM, Ramaswamy S, Mino-Kenudson M, Iafrate AJ, Benes CH, Engelman JA.

Science. 2014 Dec 19;346(6216):1480-6. doi: 10.1126/science.1254721. Epub 2014 Nov 13.

18.

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.

Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N.

Clin Cancer Res. 2015 Jan 1;21(1):166-74. doi: 10.1158/1078-0432.CCR-14-1385. Epub 2014 Oct 28.

19.

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT.

Clin Cancer Res. 2014 Nov 15;20(22):5686-96. doi: 10.1158/1078-0432.CCR-14-1511. Epub 2014 Sep 16.

20.

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA.

Cancer Discov. 2014 Jun;4(6):662-673. doi: 10.1158/2159-8290.CD-13-0846. Epub 2014 Mar 27.

21.

ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform.

Friboulet L, Postel-Vinay S, Sourisseau T, Adam J, Stoclin A, Ponsonnailles F, Dorvault N, Commo F, Saulnier P, Salome-Desmoulez S, Pottier G, André F, Kroemer G, Soria JC, Olaussen KA.

Cell Cycle. 2013 Oct 15;12(20):3298-306. doi: 10.4161/cc.26309. Epub 2013 Sep 9.

22.

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.

Postel-Vinay S, Bajrami I, Friboulet L, Elliott R, Fontebasso Y, Dorvault N, Olaussen KA, André F, Soria JC, Lord CJ, Ashworth A.

Oncogene. 2013 Nov 21;32(47):5377-87. doi: 10.1038/onc.2013.311. Epub 2013 Aug 12.

PMID:
23934192
23.

19q13-ERCC1 gene copy number increase in non--small-cell lung cancer.

Vanhecke E, Valent A, Tang X, Vielh P, Friboulet L, Tang T, Goubar A, Li Y, Robin A, Behrens C, Commo F, Validire P, André F, Wistuba II, Soria JC, Olaussen KA.

Clin Lung Cancer. 2013 Sep;14(5):549-57. doi: 10.1016/j.cllc.2013.01.006. Epub 2013 Jun 15.

PMID:
23773262
24.

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, Wilner KD, Lockerman EL, Khan TM, Mahmood S, Gainor JF, Digumarthy SR, Stone JR, Mino-Kenudson M, Christensen JG, Iafrate AJ, Engelman JA, Shaw AT.

N Engl J Med. 2013 Jun 20;368(25):2395-401. doi: 10.1056/NEJMoa1215530. Epub 2013 Jun 1.

25.

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC.

N Engl J Med. 2013 Mar 21;368(12):1101-10. doi: 10.1056/NEJMoa1214271.

26.

PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.

Olaussen KA, Adam J, Vanhecke E, Vielh P, Pirker R, Friboulet L, Popper H, Robin A, Commo F, Thomale J, Kayitalire L, Filipits M, Le Chevalier T, André F, Brambilla E, Soria JC.

Lung Cancer. 2013 May;80(2):216-22. doi: 10.1016/j.lungcan.2013.01.014. Epub 2013 Feb 12.

PMID:
23410825
27.

Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.

Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, Goubar A, Dorvault N, Lazar V, Job B, Besse B, Validire P, Girard P, Lacroix L, Hasmats J, Dufour F, André F, Soria JC.

Clin Cancer Res. 2011 Sep 1;17(17):5562-72. doi: 10.1158/1078-0432.CCR-11-0790. Epub 2011 Jul 12.

28.

Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells.

Friboulet L, Gourzones C, Tsao SW, Morel Y, Paturel C, Témam S, Uzan C, Busson P.

BMC Cancer. 2010 Jun 24;10:327. doi: 10.1186/1471-2407-10-327.

29.

Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis.

Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquère S, Ripoche H, Khabir A, Tsao SW, Bosq J, Lo KW, Busson P.

Neoplasia. 2008 Nov;10(11):1183-94.

Supplemental Content

Loading ...
Support Center